mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2009-525mrj-210Research ArticleСтатьиArticlesПерспективы применения инъекционной формы мелоксикама (Амелотекс®) у больных остеоартрозомProspects for using injectable meloxicam (Amelotex®) in patients with osteoarthrosisEliseyevM SEliseyevM S-БарсковаВ. Г.BarskovaV G-ВладимировС. А.VladimirovS A-20092503200931№1 (2009)5860Copyright © Eliseyev M.S., Барскова В.Г., Владимиров С.А., 20092009Eliseyev M.S., Барскова В.Г., Владимиров С.А.Eliseyev M.S., Barskova V.G., Vladimirov S.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/210

Представлены данные о перспективах применения в клинической практике у больных остеоартрозом нестероидного противовоспалительного препарата Амелотекс® (мелоксикам). Приводятся предварительные результаты исследования, демонстрирующего хорошую эффективность и переносимость Амелотекса®у больных гонартрозом.

The paper presents data on the prospects for clinical use of the nonsteroidal anti-inflammatory drug Amelotex® (meloxicam) in patients with osteoarthrosis. It also gives the results of a study showing a good efficacy and tolerability of Amelotex® in patients with gonarthrosis.

References<div><p>Jordan K., Arden N., Doherty M. et al. EULAR Recommendation 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the standing committee for international clinical studies including trials (ESCISIT). Ann Rheum Dis. 2003;62:1145-55.</p><p>Zhang W., Doherty M., Leeb B.F. et al. EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007;66(3):377-88.</p><p>Zhang W., Doherty M., Arden N. et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005;64(5):669-81.</p><p>Altman R.D., Hohberg M.C., Moskowitz R.W. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000;43(9):1905-15.</p><p>Zhang W., Jones A., Doherty M. Does paracetamol (acetaminophen) reduce pain of osteoarthritis? A meta-analysis of randomised controlled trials. Ann Rheum Dis 2004;63(8):901-7.</p><p>Buckley N., Eddleston M. Paracetamol (acetaminophen) poisoning. Clin Evid 2005;14:1738-44.</p><p>Towheed TE., Maxwell L., Judd M.G. et al. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev 2006;(1):CD004257.</p><p>Curtiss F.R. Relative value of the NSAIDs, including COX-2 inhibitors and meloxicam. Journal of Managed Care Pharmacy 2006;12(3):265-8.</p><p>Churchill L., Graham A.G., Shin C.K. et al. Selective inhibition of human cyclo-oxygenase-2 by meloxicam. Immunopharmacol 1996;4:125-35.</p><p>Turck D., Busch U., Heinzel G. Clinical pharmacokinetics of meloxicam. Eur J Rheumatol Inflamm 1995;15:22-34.</p><p>Tuerck D., Busch U., Heinzel G. et al. Clinical pharmacokinetics of meloxicam Drug Res 1997;47:253-8.</p><p>Lapicque F., Vergne P., Jouzeau J.-I. et al. Articular diffusion of meloxicam after a single oral dose: relationship to cyclo-oxygenase inhibition in synovial cells. Clin Pharmacokinet 2000;39:369-82.</p><p>Schmid J., Busch U., Heinzel G. et al. Local tissue tolerability of meloxicam, a new NSAID: indication for parenteral, dermal and mucosal administration. Br J Rheumatol 1996;35(suppl. 1):44-50.</p><p>Van Ryn J., Kink-Eiband M., Kuritsch I. et al. Meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers. J Clin Pharmacol 2004;44(7):777-84.</p><p>McAdam B.F., Catella-Lawson F., Mardini I.A. et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999;96:272-7.</p><p>Singh G., Graham D., Wang H. Concomitant aspirin use reduces the risk of acute myocardial infarction in users of cyclo-oxygenase-2 selective and some non-selective nonsteroidal anti-inflamma-toty drugs. Ann Rheum Dis 2006;65(suppl. II):61.</p><p>Schwartz J.I., Van Hecken A., De Lepeleire I. et al. Comparative inhibitory activity of rofecoxib (MK-0966), meloxicam, diclofenac, ibuprofcn, and naproxcn on COX-2 vs COX-1 in healthy female volunteers. Poster EULAR 1999. Ann Rheum Dis Abstr 1999;857:206.</p><p>Del Tacca M., Colucci R., Fornai M. et al. Efficacy and Tolerability of Meloxicam, a COX-2 Preferential Nonsteroidal Anti-Inflammatory. Drug Clin Drug Invest 2002;22(12):799-818.</p><p>Layton D., Hughes K., Harris S. et al. Comparison of the incidence rates of thromboem-bolic events reported for patients prescribed cele-coxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data. Rheumatology (Oxford) 2003;42:1354-640.</p><p>Chen Y.-F., Jobanputra P., Barton P. et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecox-ib, rofecoxib, etoricoxib, valdecoxib and lumiracox-ib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technology Assessment 2008;12(11).</p><p>Valat J.P., Accardo S., Reginster J.Y. et al. A comparison of the efficacy and tolerability of meloxicam and diclofenac in the treatment of patients with osteoarthritis of the lumbar spine. Inflamm Res 2001;50(1):30-4.</p><p>Dougados M. et al. Ankylosing spondylitis: what is the optimum duration of a clinical study? One year versus a 6 weeks non-steroidal anti-inflammatory drug trial. Rheumatol (Oxford) 1999;38:235-44.</p><p>Hawkey C., Kahan A., Steinbruck K. et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. Br J Rheumatol 1998;37: 937-45.</p><p>Dequeker J., Hawkey C., Kahan A. et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxi-cam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthri-tis. Br J Rheumatol 1998;37:946-51.</p><p>Bassleer C., Magotteaux J., Geenen V. et al. Effects of meloxicam compared to acetylsalicylic acid in human articular chondrocytes. Pharmacology 1997;54(1):49-56.</p><p>Mohr W., Lehmann H., Engelhardt G. Chondroneutrality of meloxicam in rats with spontaneous osteoarthrosis of the ankle joint. J Rheumatol 1997;56:21-30.</p><p>Ding C. Do NSAIDs affect the progression of osteoarthritis? Inflammation 2002;26(3):139-42.</p><p>Engelhardt G., Homma D., Schnitzler C. Meloxicam: a potent inhibitor of adjuvant arthritis in the Lewis rat. Inflamm Res 1995;44(12):548-55.</p><p>Lin S.K., Kok S.H., Kuo M.Y. et al. Sequential expressions of MMP-1, TIMP-1, IL-6, and COX-2 genes in induced periapical lesions in rats. Eur J Oral Sci 2002;110(3):246-53.</p><p>Иониченок Н.Г Клиническая и инструментальная оценка эффективности и переносимости фармакотерапии остеоартроза коленных суставов. Автореф. дис. ... канд. мед. наук. М., 2005;23.</p><p>Combe B., Vеlicitat P., Garzon N. et al. Comparison of intramuscular and oral meloxicam in rheumatoid arthritis patients. Inflamm Res 2001; 50(suppl. 1):10-6.</p><p>Euller-Ziegler L., Vеlicitat P, Bluhmki E. et al. B.Meloxicam: a review of its pharmacokinetics, efficacy and tolerability following intramuscular administration. Inflamm Res 2001;50(suppl. 1):5-9.</p><p>Цветкова Е.С. Эффективность и переносимость ступенчатой терапии мовалисом (мелоксикамом) при ревматических заболеваниях. Тер арх 2004;76(12):78-80.</p><p>Хитров Н.А. Современные пути лечения остеоартроза. РМЖ 2008;26:1778-82.</p></div><br /><div><p>Jordan K., Arden N., Doherty M. et al. EULAR Recommendation 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the standing committee for international clinical studies including trials (ESCISIT). Ann Rheum Dis. 2003;62:1145-55.</p><p>Zhang W., Doherty M., Leeb B.F. et al. EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007;66(3):377-88.</p><p>Zhang W., Doherty M., Arden N. et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005;64(5):669-81.</p><p>Altman R.D., Hohberg M.C., Moskowitz R.W. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000;43(9):1905-15.</p><p>Zhang W., Jones A., Doherty M. Does paracetamol (acetaminophen) reduce pain of osteoarthritis? A meta-analysis of randomised controlled trials. Ann Rheum Dis 2004;63(8):901-7.</p><p>Buckley N., Eddleston M. Paracetamol (acetaminophen) poisoning. Clin Evid 2005;14:1738-44.</p><p>Towheed TE., Maxwell L., Judd M.G. et al. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev 2006;(1):CD004257.</p><p>Curtiss F.R. Relative value of the NSAIDs, including COX-2 inhibitors and meloxicam. Journal of Managed Care Pharmacy 2006;12(3):265-8.</p><p>Churchill L., Graham A.G., Shin C.K. et al. Selective inhibition of human cyclo-oxygenase-2 by meloxicam. Immunopharmacol 1996;4:125-35.</p><p>Turck D., Busch U., Heinzel G. Clinical pharmacokinetics of meloxicam. Eur J Rheumatol Inflamm 1995;15:22-34.</p><p>Tuerck D., Busch U., Heinzel G. et al. Clinical pharmacokinetics of meloxicam Drug Res 1997;47:253-8.</p><p>Lapicque F., Vergne P., Jouzeau J.-I. et al. Articular diffusion of meloxicam after a single oral dose: relationship to cyclo-oxygenase inhibition in synovial cells. Clin Pharmacokinet 2000;39:369-82.</p><p>Schmid J., Busch U., Heinzel G. et al. Local tissue tolerability of meloxicam, a new NSAID: indication for parenteral, dermal and mucosal administration. Br J Rheumatol 1996;35(suppl. 1):44-50.</p><p>Van Ryn J., Kink-Eiband M., Kuritsch I. et al. Meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers. J Clin Pharmacol 2004;44(7):777-84.</p><p>McAdam B.F., Catella-Lawson F., Mardini I.A. et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999;96:272-7.</p><p>Singh G., Graham D., Wang H. Concomitant aspirin use reduces the risk of acute myocardial infarction in users of cyclo-oxygenase-2 selective and some non-selective nonsteroidal anti-inflamma-toty drugs. Ann Rheum Dis 2006;65(suppl. II):61.</p><p>Schwartz J.I., Van Hecken A., De Lepeleire I. et al. Comparative inhibitory activity of rofecoxib (MK-0966), meloxicam, diclofenac, ibuprofcn, and naproxcn on COX-2 vs COX-1 in healthy female volunteers. Poster EULAR 1999. Ann Rheum Dis Abstr 1999;857:206.</p><p>Del Tacca M., Colucci R., Fornai M. et al. Efficacy and Tolerability of Meloxicam, a COX-2 Preferential Nonsteroidal Anti-Inflammatory. Drug Clin Drug Invest 2002;22(12):799-818.</p><p>Layton D., Hughes K., Harris S. et al. Comparison of the incidence rates of thromboem-bolic events reported for patients prescribed cele-coxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data. Rheumatology (Oxford) 2003;42:1354-640.</p><p>Chen Y.-F., Jobanputra P., Barton P. et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecox-ib, rofecoxib, etoricoxib, valdecoxib and lumiracox-ib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technology Assessment 2008;12(11).</p><p>Valat J.P., Accardo S., Reginster J.Y. et al. A comparison of the efficacy and tolerability of meloxicam and diclofenac in the treatment of patients with osteoarthritis of the lumbar spine. Inflamm Res 2001;50(1):30-4.</p><p>Dougados M. et al. Ankylosing spondylitis: what is the optimum duration of a clinical study? One year versus a 6 weeks non-steroidal anti-inflammatory drug trial. Rheumatol (Oxford) 1999;38:235-44.</p><p>Hawkey C., Kahan A., Steinbruck K. et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. Br J Rheumatol 1998;37: 937-45.</p><p>Dequeker J., Hawkey C., Kahan A. et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxi-cam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthri-tis. Br J Rheumatol 1998;37:946-51.</p><p>Bassleer C., Magotteaux J., Geenen V. et al. Effects of meloxicam compared to acetylsalicylic acid in human articular chondrocytes. Pharmacology 1997;54(1):49-56.</p><p>Mohr W., Lehmann H., Engelhardt G. Chondroneutrality of meloxicam in rats with spontaneous osteoarthrosis of the ankle joint. J Rheumatol 1997;56:21-30.</p><p>Ding C. Do NSAIDs affect the progression of osteoarthritis? Inflammation 2002;26(3):139-42.</p><p>Engelhardt G., Homma D., Schnitzler C. Meloxicam: a potent inhibitor of adjuvant arthritis in the Lewis rat. Inflamm Res 1995;44(12):548-55.</p><p>Lin S.K., Kok S.H., Kuo M.Y. et al. Sequential expressions of MMP-1, TIMP-1, IL-6, and COX-2 genes in induced periapical lesions in rats. Eur J Oral Sci 2002;110(3):246-53.</p><p>Иониченок Н.Г Клиническая и инструментальная оценка эффективности и переносимости фармакотерапии остеоартроза коленных суставов. Автореф. дис. ... канд. мед. наук. М., 2005;23.</p><p>Combe B., Vеlicitat P., Garzon N. et al. Comparison of intramuscular and oral meloxicam in rheumatoid arthritis patients. Inflamm Res 2001; 50(suppl. 1):10-6.</p><p>Euller-Ziegler L., Vеlicitat P, Bluhmki E. et al. B.Meloxicam: a review of its pharmacokinetics, efficacy and tolerability following intramuscular administration. Inflamm Res 2001;50(suppl. 1):5-9.</p><p>Цветкова Е.С. Эффективность и переносимость ступенчатой терапии мовалисом (мелоксикамом) при ревматических заболеваниях. Тер арх 2004;76(12):78-80.</p><p>Хитров Н.А. Современные пути лечения остеоартроза. РМЖ 2008;26:1778-82.</p></div><br />

The authors declare that there are no conflicts of interest present.